<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1229">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04673162</url>
  </required_header>
  <id_info>
    <org_study_id>RCT-MP-COVID-19</org_study_id>
    <nct_id>NCT04673162</nct_id>
  </id_info>
  <brief_title>Evaluation of the Efficacy of High Doses of Methylprednisolone in SARS-CoV2 ( COVID-19) Pneumonia Patients</brief_title>
  <official_title>A Randomized, Multicentre, Double-blind Study to Evaluate the Efficacy of High-dose Administration of Methylprednisolone in Addition to Standard Treatment, in SARS-CoV2 (COVID-19) Pneumonia Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda Unità Sanitaria Locale Reggio Emilia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Azienda Unità Sanitaria Locale Reggio Emilia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This double blind, randomized study is aiming to evaluate the efficacy of three doses&#xD;
      (1gr/day) of methylpredisolone added to standard therapy in patients, with documented&#xD;
      COVID-19 pneumonia, requiring hospitalization but not mechanical ventilation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients recently hospitalized for the treatment of documented COVID-19 pneumonia who do not&#xD;
      require invasive ventilation will be randomized (1:1) to receive current standard treatment,&#xD;
      which may include desamethasone and oxygen, with methylprenisolone 1gr daily iv for 3&#xD;
      consecutive days or standard treatment alone.&#xD;
&#xD;
      Efficacy measures will be time to recovery (discharge from hospital), invasive ventilation&#xD;
      prevention and survival.&#xD;
&#xD;
      Patients safety will be evaluated throughout the all study period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2020</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">April 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, multicentric, double blind</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Placebo controlled</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Length of hospitalization</measure>
    <time_frame>30 days since randomisation</time_frame>
    <description>the interval between randomization and discharge from the hospital without the need for supplemental oxygen</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">260</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>A SOC plus MP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard treatment (currently desamethasone 6mg/daily for 10 days) plus Methylprednisolone 1gr daily iv on days 1,2,3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B SOC plus Pb</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard treatment (currently desamethasone 6mg/daily for 10 days) plus Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylprednisolone, Placebo</intervention_name>
    <description>iv administration</description>
    <arm_group_label>A SOC plus MP</arm_group_label>
    <arm_group_label>B SOC plus Pb</arm_group_label>
    <other_name>Standard treatment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. age = 18 years;&#xD;
&#xD;
          2. Informed consent for participation in the study and for data processing;&#xD;
&#xD;
          3. Molecular diagnosis with Polymerase Chain Reaction (PCR) test of Sars-CoV2 infection;&#xD;
&#xD;
          4. Hospitalization in a specialist ward for Covid-19 patient care (eg., Infectious&#xD;
             Diseases, Pulmonology or Internal Medicine);&#xD;
&#xD;
          5. Need for supplemental oxygen in any delivery mode with the exception of invasive&#xD;
             mechanical ventilation;&#xD;
&#xD;
          6. PaO2 / FiO2 between 100 and 300 mmHg.&#xD;
&#xD;
          7. Clinical / instrumental diagnosis (high resolution chest CT scan or chest x-ray or&#xD;
             lung ultrasound) of interstitial pneumonia for no more than three days;&#xD;
&#xD;
          8. Serum CRP greater than 5 mg / dL;&#xD;
&#xD;
          9. Interval from onset of SARS-CoV2 infection symptoms to randomization&gt; 5 days-&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Invasive mechanical ventilation;&#xD;
&#xD;
          2. Presence of shock or concomitant organ failure that requires admission to the&#xD;
             Intensive Care Unit;&#xD;
&#xD;
          3. Pregnancy or breastfeeding;&#xD;
&#xD;
          4. Severe heart or kidney failure;&#xD;
&#xD;
          5. Known hypersensitivity to methylprednisolone, to dexamethasone or to an exception;&#xD;
&#xD;
          6. Diabetes not compensated according to the doctor's judgment;&#xD;
&#xD;
          7. Other clinical conditions that contraindicate Methylprednisolone and cannot be treated&#xD;
             or resolved according to the doctor's judgment;&#xD;
&#xD;
          8. Steroid bolus therapy in the week prior to enrollment for the study;&#xD;
&#xD;
          9. Enrollment in another clinical trial;&#xD;
&#xD;
         10. Patient already randomized in this study-&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Massimo Costantini, MD</last_name>
    <role>Study Chair</role>
    <affiliation>AUSL-IRCCS di Reggio Emilia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Massimo Costantini, MD</last_name>
    <phone>+390522296986</phone>
    <email>massimo.costantini@ausl.re.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>SOC Pneumologia, SOC Malattie Infettive, SOC Reumatologia, Az USL-IRCCS di Reggio Emilia</name>
      <address>
        <city>Reggio Emilia</city>
        <zip>42122</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Massimo Costantini, MD</last_name>
      <email>Massimo.Costantini@ausl.re.it</email>
    </contact>
    <investigator>
      <last_name>Nicola Facciolongo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marco Massari, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carlo Salvarani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 16, 2020</study_first_submitted>
  <study_first_submitted_qc>December 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 17, 2020</study_first_posted>
  <last_update_submitted>December 16, 2020</last_update_submitted>
  <last_update_submitted_qc>December 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Covid19</keyword>
  <keyword>Methylprednisolone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Acetate</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>all IPD that underlie results in a publication</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>As soon as the main results have been published</ipd_time_frame>
    <ipd_access_criteria>publication reviewers</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

